Parkinson Hastalığı

Beal MF. (1995). Aging, energy, and oxidative stress in neurodegenerative diseases. Annals of neurology, 38(3), 357–366. https://doi.org/10.1002/ana.410380304
Gerlach M, & Riederer P. (1996). Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. Journal of neural transmission, 103, 987-1041. https://doi.org/10.1007/BF01291788
Akbayır E, Şen M, Ay U, et al. Parkinson hastalığının etyopatogenezi. Deneysel Tıp Araştırma Enstitüsü Dergisi, 2017; 7(13): 1-23.
Williams DR, & Litvan I. (2013). Parkinsonian syndromes. Continuum: lifelong learning in neurology, 19(5), 1189-1212. https://doi.org/10.1212/01.CON.0000436152.24038.e0
Mutluay SU. Bazal Ganglia ve Hipokampuse Unilateral Aav Aracılı Alfa-Sinükleinin Enjeksiyonu ile Oluşturulan Parkinson Hastalığı Modelinin Davranışsal ve Patolojik Olarak Değerlendirilmesi. Farmakoloji Programı [Yüksek Lisans Tezi], Ankara: Hacettepe Üniversitesi, 2017.
Tysnes OB, & Storstein A. (2017). Epidemiology of Parkinson’s disease. Journal of neural transmission, 124, 901-905. https://doi.org/10.1007/s00702-017-1686-y
Bekris LM, Mata IF, & Zabetian, C. P. (2010). The genetics of Parkinson disease. Journal of geriatric psychiatry and neurology, 23(4), 228-242. https://doi.org/10.1177/0891988710383572
Rajput AH, & Birdi S. (1997). Epidemiology of Parkinson's disease. Parkinsonism & related disorders, 3(4), 175-186. https://doi.org/10.1016/s1353-8020(97)00029-1
Çakmur R. (2003). Parkinson hastalığının epidemiyolojisi ve klinik özellikleri. Türkiye Klinikleri Journal of Neurology, 1(3), 160-163.
Smith Y, Bevan MD, Shink, E, et al. (1998). Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience, 86(2), 353-387. https://doi.org/10.1016/s0306-4522(98)00004-9
Balestrino R, & Schapira AHV. (2020). Parkinson disease. European journal of neurology, 27(1), 27-42. https://doi.org/10.1111/ene.14108
Hoehn MM, & Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1998; 50(2): 318-318. https://doi.org/10.1212/wnl.50.2.318
Dexter DT, & Jenner P. (2013). Parkinson disease: from pathology to molecular disease mechanisms. Free Radical Biology and Medicine, 62, 132-144. https://doi.org/10.1016/j.freeradbiomed.2013.01.018
Wakabayashi K, Tanji K, Odagiri S, et al. (2013). The Lewy body in Parkinson’s disease and related neurodegenerative disorders. Molecular neurobiology, 47, 495-508. https://doi.org/10.1007/s12035-012-8280-y
Braak H, Del Tredici K, Rüb U, et al. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of aging, 24(2), 197-211. https://doi.org/10.1016/s0197-4580(02)00065-9
Mortimer JA, Pirozzolo FJ, Hansch EC, et al. (1982). Relationship of motor symptoms to intellectual deficits in Parkinson disease. Neurology, 32(2), 133-137. https://doi.org/10.1212/wnl.32.2.133
Boteva E, & Mironova R. (2019). Maillard reaction and aging: can bacteria shed light on the link?. Biotechnology & Biotechnological Equipment, 33(1), 481-497.
Lima MM, Martins EF, Delattre AM, et al. (2012). Motor and non-motor features of Parkinson's disease - a review of clinical and experimental studies. CNS & neurological disorders drug targets, 11(4), 439–449. https://doi.org/10.2174/187152712800792893
Sharma N, Jamwal S, Singh S, et al. (2017). Animal Models of Parkinson’s Disease. Animal Models of Neurological Disorders: Principle and Working Procedure for Animal Models of Neurological Disorders, 23-42.
Betarbet R, & Greenamyre JT. (2008). Complex I Inhibition, Rotenone and Parkinson's Disease. In Parkinson's Disease (pp. 195-206). Academic Press.
Cannon JR, Tapias V, Na HM, et al. (2009). A highly reproducible rotenone model of Parkinson's disease. Neurobiology of disease, 34(2), 279–290. https://doi.org/10.1016/j.nbd.2009.01.016
Greenamyre JT, Cannon JR, Drolet R, et al. (2010). Lessons from the rotenone model of Parkinson's disease. Trends in pharmacological sciences, 31(4), 141–143. https://doi.org/10.1016/j.tips.2009.12.006
Przedborski S, Levivier M, Jiang H, et al. (1995). Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience, 67(3), 631–647. https://doi.org/10.1016/0306-4522(95)00066-r
Blesa J, Phani S, Jackson-Lewis V, et al. (2012). Classic and new animal models of Parkinson's disease. Journal of biomedicine & biotechnology, 2012, 845618. https://doi.org/10.1155/2012/845618
Gubellini P, & Kachidian P. (2015). Animal models of Parkinson's disease: An updated overview. Revue neurologique, 171(11), 750–761. https://doi.org/10.1016/j.neurol.2015.07.011
Büeler H. (2009). Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Experimental neurology, 218(2), 235–246. https://doi.org/10.1016/j.expneurol.2009.03.006
Manning-Bog AB, McCormack AL, Li J, et al. (2002). The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. The Journal of biological chemistry, 277(3), 1641–1644. https://doi.org/10.1074/jbc.C100560200
Bansal PK, Deshmukh R.(Eds). Animal Models of Neurological Disorders. Springer Nature Singapore. 2017; 23-43.